The gene TET3 (tet methylcytosine dioxygenase 3) is mapped to human chromosome 2p13.1. The encoded enzyme is dependent on a-ketoglutarate and Fe2+.
Synonyms: Anti-MGC22014; Anti-hCG_40738; Anti-tet methylcytosine dioxygenase 3
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: TET3 (tet methylcytosine dioxygenase 3) is responsible for the conversion of 5-methylcytosine to 5-hydroxymethylcytosine (5hmC). 5hmC is a DNA modification and various cancers have low levels of 5hmC. TET proteins suppress haematopoietic transformation and also inhibit breast and prostate cancer invasion as well as metastasis. TET3 also suppresses growth and self-renewal in glioblastoma stem cells. The gene is downregulated in endometriosis. TET3 is overexpressed in oocytes and zygotes. It is required for epigenetic reprogramming of the zygotic DNA from paternal side.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC